Can Zoetis Stock Jump 30%?

For questions about this article or underlying research, email help@trefis.com.

Zoetis (ZTS) stock trades 45.1% below its high of October 27, 2025. A 30% jump in the stock depends on whether the company can maintain its cash generation. Gains of that size are common for Zoetis, which has climbed that much within the year in 8 of the last 10 calendar years. Its free cash flow equals 6.8% of its market value, compared with 4.3% for the median S&P 500 company. That is the mark of a business that is either on sale or expected to shrink. So is that cash as solid as it looks?

Zoetis Has Produced More Cash Each Year Since 2023

So far it is. Zoetis produced $2.32 billion of free cash flow in the twelve months to June 2026. That figure is up from $1.29 billion in the twelve months to June 2023, and the total rose in each year between. Just like profit, that cash belongs to shareholders whether or not it is paid out. When the market recognizes cash that keeps growing, the share price tends to follow.

Zoetis sells animal health products for pets and livestock. Its largest product line, parasiticides, brought in $2.34 billion in fiscal 2025. The business keeps a large portion of what it sells, posting an operating margin of 37.6% over the last twelve months, against 18.5% for the S&P 500. Most of the cash from operations is left over, as capital spending consumed just 18.5% of it.

Lenders also have a claim on the business. Total debt reached $9.24 billion at the end of June 2026, up from $6.79 billion a year earlier. Over those twelve months, Zoetis spent $3.64 billion buying back shares. That total exceeded its free cash flow, and management said part of the buybacks was funded with convertible debt. Net of cash, that debt equals 22.4% of Zoetis’s market value. Measured against market value plus net debt, the free cash yield is 5.6% rather than 6.8%.

Zoetis Expects Lower Sales As Pet Owners Cut Back

The market’s doubt appears to center on the pet business. This unit is the main reason management now expects total sales to shrink in fiscal 2026. In August, Zoetis cut its fiscal 2026 revenue guidance to a midpoint of $9.22 billion, down from $9.82 billion in May. That falls below the $9.47 billion it reported for fiscal 2025. That remains a forecast: reported revenue for the twelve months to June 2026 was $9.52 billion, up 1.5% from a year earlier.

Management blamed the cut on clinic visit declines, more value-conscious pet owners, and heavier promotions by rivals, particularly in Dermatology and U.S. parasiticides. On the August 6, 2026 call, management also said a new competitor in U.S. dermatology will keep Zoetis’s volume and market share under pressure. In fiscal Q2 2026, Companion Animal revenue was $1.7 billion, down 6%. Key Dermatology fell 16% to $395 million, while Livestock grew 11% to $731 million.

Management is responding with cost and productivity actions, and with promotions and bundled discounts to protect its share at clinics while keeping list prices unchanged. So far, the fall in total sales is guided rather than reported, though the pet business already shrank in fiscal Q2, and the cash has not fallen.

Is Zoetis’s Cash Steady Or Still Growing?

Lately, the cash has been steady rather than growing. Twelve-month free cash flow stayed between $2.24 billion and $2.32 billion at each of the last five quarter ends. Zoetis has yet to show that the cash can keep growing while management expects sales to fall in fiscal 2026. Its debt is well covered for now, with operating income at 15.1 times interest expense over the last twelve months.

Zoetis’s next quarterly report, covering the three months to September 2026, is the next test, and its twelve-month free cash flow is the number to watch.

Does This Mean You Should Act On ZTS?

Our purpose is to inform you with unique data so you make the right investment decisions. That said, betting on a single stock is always risky, no matter which direction you choose.

There is a smarter approach. Since its inception, the Trefis High Quality (HQ) Portfolio has returned 105%, beating the benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. And it did so without taking the concentrated risk that comes with do-it-yourself stock picking. If that is how you want to invest, the HQ Portfolio is the place to start.

Spot an error or want more like this? Tell us in 10 seconds.